BioCentury | Aug 22, 2020
Emerging Company Profile

Luminary: turning cell engineering tools into therapies

...Inc. (NASDAQ:PSTX), which uses the piggyBac transposon system; and Ziopharm Oncology Inc....
...isn’t as advanced as that of Poseida or Ziopharm...
BioCentury | Jul 7, 2020
Emerging Company Profile

Tessera: engineering mobile genetic elements for gene insertion

...ex vivo delivery such as CAR T cells. Companies including Avalon GloboCare Corp. (NASDAQ:AVCO) and Ziopharm Oncology Inc....
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...NASDAQ:AUTL). CAR T pioneer Carl June will lead the newly formed scientific advisory board of Ziopharm Oncology Inc....
...role on an interim basis. Eck was CMO of Immatics Biotechnologies GmbH. Robin Sawka, BioCentury Staff Novavax Inc. Ziopharm Oncology Inc. Dewpoint...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...which does not expect to begin a CEO search until the “COVID-19 situation is stabilized.” Ziopharm Oncology Inc....
...Technologies Inc. Amphista Therapeutics Ltd. Science 37 Inc. Amylyx Pharmaceutical Oligomerix Inc. Galecto Inc. Applied Therapeutics Inc. Relmada Therapeutics Inc. Kinnate Biopharma Inc. Immunomedics Inc. Ziopharm Oncology Inc....
BioCentury | Feb 6, 2020
Finance

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

...Ziopharm raise over $140 million via follow-ons Two biotechs raised over $140 million in follow-ons. Ziopharm Oncology Inc....
...its IP portfolio and establishing a laboratory. Elizabeth S. Eaton, Staff Writer Aimmune Therapeutics Inc. Vineti Inc. MaaT Pharma S.A. Ziopharm Oncology Inc. Ikarovec...
BioCentury | Jul 24, 2019
Company News

July 24 Management tracks: GSK, Goldman Sachs, Ziopharm and Alkahest

...covering healthcare investment banking in Asia and previously worked at BofA Merrill Lynch. Immunotherapy company Ziopharm Oncology Inc....
...Complete Genomics Inc., a subsidiary of BGI Group (Shenzhen, China). Jonathan Block, Associate Editor Alkahest Inc. GlaxoSmithKline plc Goldman Sachs Ziopharm Oncology Inc....
BioCentury | Jun 13, 2019
Emerging Company Profile

Gracell: Speeding up CAR T cells

...or co-development. At least one other company has developed a rapid CAR T manufacturing platform. Ziopharm Oncology Inc....
...its high transfection efficiency and cell purity. "The process can be further shortened," he added. Ziopharm...
...Foster City, Calif. Gracell Biotechnologies Co. Ltd., Suzhou, China Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Ziopharm Oncology Inc....
BioCentury | May 23, 2019
Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

...Therapeutics Inc. Intrexon's RheoSwitch technology, licensed by Ziopharm Oncology Inc. in 2011, can create small molecule-responsive proteins. Ziopharm's...
...its proteins, giving it more flexibility over safety and efficacy than Ziopharm. And unlike Obsidian, Ziopharm...
...an extensive safety record and clinical experience is a significant advantage" for Obsidian, Wotton said. Ziopharm...
BioCentury | Dec 18, 2018
Company News

Management tracks: AbbVie, Semma, Ziopharm

...Stanford University (Stanford, Calif.). Ziopharm Oncology Inc. (NASDAQ:ZIOP) promoted EVP and CBO David Mauney to president. A Ziopharm...
BioCentury | Nov 16, 2018
Financial News

Ziopharm raises $50M in private placement

...Immunotherapy company Ziopharm Oncology Inc. (NASDAQ:ZIOP) raised $50 million through the sale of 18.9 million units at $2.64...
...Management and Level One Partners. Raymond James was the placement agent. Ziopharm Oncology Inc. (NASDAQ:ZIOP), Boston, Mass. Alicia Parker Ziopharm Oncology Inc....
Items per page:
1 - 10 of 258
BioCentury | Aug 22, 2020
Emerging Company Profile

Luminary: turning cell engineering tools into therapies

...Inc. (NASDAQ:PSTX), which uses the piggyBac transposon system; and Ziopharm Oncology Inc....
...isn’t as advanced as that of Poseida or Ziopharm...
BioCentury | Jul 7, 2020
Emerging Company Profile

Tessera: engineering mobile genetic elements for gene insertion

...ex vivo delivery such as CAR T cells. Companies including Avalon GloboCare Corp. (NASDAQ:AVCO) and Ziopharm Oncology Inc....
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

...NASDAQ:AUTL). CAR T pioneer Carl June will lead the newly formed scientific advisory board of Ziopharm Oncology Inc....
...role on an interim basis. Eck was CMO of Immatics Biotechnologies GmbH. Robin Sawka, BioCentury Staff Novavax Inc. Ziopharm Oncology Inc. Dewpoint...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...which does not expect to begin a CEO search until the “COVID-19 situation is stabilized.” Ziopharm Oncology Inc....
...Technologies Inc. Amphista Therapeutics Ltd. Science 37 Inc. Amylyx Pharmaceutical Oligomerix Inc. Galecto Inc. Applied Therapeutics Inc. Relmada Therapeutics Inc. Kinnate Biopharma Inc. Immunomedics Inc. Ziopharm Oncology Inc....
BioCentury | Feb 6, 2020
Finance

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

...Ziopharm raise over $140 million via follow-ons Two biotechs raised over $140 million in follow-ons. Ziopharm Oncology Inc....
...its IP portfolio and establishing a laboratory. Elizabeth S. Eaton, Staff Writer Aimmune Therapeutics Inc. Vineti Inc. MaaT Pharma S.A. Ziopharm Oncology Inc. Ikarovec...
BioCentury | Jul 24, 2019
Company News

July 24 Management tracks: GSK, Goldman Sachs, Ziopharm and Alkahest

...covering healthcare investment banking in Asia and previously worked at BofA Merrill Lynch. Immunotherapy company Ziopharm Oncology Inc....
...Complete Genomics Inc., a subsidiary of BGI Group (Shenzhen, China). Jonathan Block, Associate Editor Alkahest Inc. GlaxoSmithKline plc Goldman Sachs Ziopharm Oncology Inc....
BioCentury | Jun 13, 2019
Emerging Company Profile

Gracell: Speeding up CAR T cells

...or co-development. At least one other company has developed a rapid CAR T manufacturing platform. Ziopharm Oncology Inc....
...its high transfection efficiency and cell purity. "The process can be further shortened," he added. Ziopharm...
...Foster City, Calif. Gracell Biotechnologies Co. Ltd., Suzhou, China Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Ziopharm Oncology Inc....
BioCentury | May 23, 2019
Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

...Therapeutics Inc. Intrexon's RheoSwitch technology, licensed by Ziopharm Oncology Inc. in 2011, can create small molecule-responsive proteins. Ziopharm's...
...its proteins, giving it more flexibility over safety and efficacy than Ziopharm. And unlike Obsidian, Ziopharm...
...an extensive safety record and clinical experience is a significant advantage" for Obsidian, Wotton said. Ziopharm...
BioCentury | Dec 18, 2018
Company News

Management tracks: AbbVie, Semma, Ziopharm

...Stanford University (Stanford, Calif.). Ziopharm Oncology Inc. (NASDAQ:ZIOP) promoted EVP and CBO David Mauney to president. A Ziopharm...
BioCentury | Nov 16, 2018
Financial News

Ziopharm raises $50M in private placement

...Immunotherapy company Ziopharm Oncology Inc. (NASDAQ:ZIOP) raised $50 million through the sale of 18.9 million units at $2.64...
...Management and Level One Partners. Raymond James was the placement agent. Ziopharm Oncology Inc. (NASDAQ:ZIOP), Boston, Mass. Alicia Parker Ziopharm Oncology Inc....
Items per page:
1 - 10 of 258